Hutchison China Meditech Ltd (HCM)


Latest News

Chi-Med and AZ present encouraging data on lung cancer drug

Hutchison China Meditech has announced that savolitinib - the lung cancer drug being developed in collaboration with As...

Savolitinib Shows Encouraging Clinical Activity

RNS Number: 7831T Hutchison China Meditech Limited 17 October 2017 Chi-Med and AstraZeneca's Savolitinib Shows Encouraging Clinical Activity in Second-Line EGFR Mutation-Positive Lung Cancer with MET -Amplification - Data for savolitinib in combination with Tagrisso or Iressa presented at World Conference on Lung Cancer- - New data give insights in...

Chi-Med reports 'promising data' on lung cancer drug

Hutchison China MediTech has reported preliminary clinical activity, safety, and tolerability data of fruquintinib, an inve...

Chi-Med Reports Preliminary Phase II data

RNS Number: 6323T Hutchison China Meditech Limited 16 October 2017 Press Release Chi-Med Reports Preliminary Phase II data on Fruquintinib Combination in First-Line Lung Cancer - Fruquintinib in combination with Iressa (gefitinib) shows promising efficacy and an acceptable safetyprofile- - Further validation of strong potential for use of fruquintinib in co...

All News

17-10-17Chi-Med and AZ present encouraging data on lung cancer drug StockMarketWire
17-10-17Savolitinib Shows Encouraging Clinical ActivityRNS
16-10-17Chi-Med reports 'promising data' on lung cancer drugStockMarketWire
16-10-17Chi-Med Reports Preliminary Phase II dataRNS
12-10-17Appointment of DirectorRNS
29-09-17Best AIM companies of 2017 Interactive Investor
29-09-17Savolitinib and Fruquintinib presentations at WCLCRNS
29-09-17Total Voting RightsRNS
29-09-17Oral Presentations at CSCO Annual MeetingRNS
31-08-17Director's Share DealingRNS
29-08-17Chi-Med starts clinical trial of Inhibitor in lymphoma patients StockMarketWire
29-08-17Start of HMPL 689 Phase I Trial in ChinaRNS
22-08-17Director's Share DealingRNS
18-08-17Directors' Share DealingRNS
15-08-17Directors' Share DealingRNS
10-08-17Director's Share DealingRNS
07-08-17Director Deals - Hutchison China Meditech Ltd (HCM)StockMarketWire
07-08-17Director Deals - Hutchison China Meditech Ltd (HCM)StockMarketWire
07-08-17Directors' Share DealingRNS
31-07-17Chi-Med revenues up 21%StockMarketWire
31-07-17Chi-Med Reports 2017 Interim ResultsRNS
30-06-17Total Voting RightsRNS
29-06-17Chi-Med and AZ start global trial of renal cancer drug StockMarketWire
29-06-17Chi-Med to Announce 2017 HY Financial ResultsRNS
29-06-17Blocklisting Six Monthly ReturnRNS
29-06-17Start of Savolitinib Global PRCC Phase III TrialRNS
22-06-17Chi-Med starts clinical trial in China StockMarketWire
22-06-17Chi-Med starts Ph I/II Trial of HMPL 453 in ChinaRNS
16-06-17Director's Share DealingRNS
12-06-17Fruquintinib NDA for Advanced CRC Filed with CFDARNS
06-06-17Fruquintinib data highlighted at ASCO, says Chi-MedStockMarketWire
06-06-17Phase III Fruquintinib Data presented at ASCORNS
02-06-1712 AIM shares in the 1,000% clubInteractive Investor
18-05-17Broker Forecast - Panmure Gordon issues a broker note on Hutchison China Meditech LtdStockMarketWire
18-05-17Chi-Med Presents Clinical Data at ASCO 2017RNS
28-04-17Total Voting RightsRNS
27-04-17Results of Annual General MeetingRNS
13-04-17Why Shell was kicked out of this top-performing portfolioInteractive Investor
07-04-17Chi-Med present pre-clinical data at AACRStockMarketWire
07-04-17Pre-clinical Data Presented at AACRRNS

RSS feeds

  • Editorial news feed for LSE:HCM Editorial
  • Regulatory news feed for LSE:HCM Regulatory